Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03141177 · ClinicalTrials.gov registry record · Phase 3

A Study of Nivolumab Combined With Cabozantinib Compared to Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma

A Phase 3 study of Renal Cell Carcinoma, sponsored by Bristol-Myers Squibb.

Active
Registry status
Phase 3
Development phase
701
Enrollment target
20
Study locations

NCT03141177 is a Phase 3 study of Renal Cell Carcinoma that is active but no longer recruiting, run by Bristol-Myers Squibb. The registered enrollment target is 701 participants, above the 237-participant average among 121 other Renal Cell Carcinoma trials with a reported enrollment target (196% higher). The trial reports 20 study locations across 11 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03141177, a Phase 3 study of Renal Cell Carcinoma, is active but no longer recruiting, sponsored by Bristol-Myers Squibb.

ACTIVE NOT RECRUITING
Registry status
Phase 3
Development phase
701 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to determine whether Nivolumab Combined with Cabozantinib is safe and effective compared to Sunitinib in previously untreated advanced or metastatic renal cell carcinoma

Conditions Studied

Renal Cell Carcinoma

Interventions

  • DRUG Sunitinib
  • BIOLOGICAL Nivolumab
  • DRUG Cabozantinib
  • BIOLOGICAL Ipilimumab

Study Locations (20)

California

  • Local Institution - 0133 - Bakersfield
  • Local Institution - 0093 - Los Angeles
  • Local Institution - 0090 - Redondo Beach
  • Local Institution - 0088 - San Luis Obispo
  • Central Coast Medical Oncology Corporation - Santa Maria

Arizona

  • Local Institution - 0044 - Goodyear
  • Local Institution - 0132 - Tucson

Georgia

  • Local Institution - 0127 - Athens
  • Local Institution - 0086 - Newnan

Illinois

  • Local Institution - 0036 - Chicago
  • Local Institution - 0042 - Zion

Massachusetts

  • Local Institution - 0113 - Boston
  • Local Institution - 0037 - Boston

Missouri

  • Local Institution - 0106 - Kansas City
  • Local Institution - 0035 - St Louis

Alabama

  • Local Institution - 0077 - Daphne

Colorado

  • Local Institution - 0103 - Aurora

Trial Details

FieldValue
Enrollment Target 701 participants
Start Date 2017-07-23
Est. Completion 2026-01-16
Phase Phase 3

Sponsor

Bristol-Myers Squibb

1,025 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03141177

The ClinicalTrials.gov registry entry for NCT03141177 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 701 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 237-participant average among 121 other Renal Cell Carcinoma trials with a reported enrollment target (196% higher). The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Renal Cell Carcinoma appearing as the primary indexed condition, and to 4 interventions - of which Sunitinib is the first listed.

NCT03141177 reports 20 study locations spanning 11 distinct geographic areas - top geographies include California, Arizona, Georgia.

Frequently Asked Questions

What is clinical trial NCT03141177 about?

NCT03141177 is a clinical study titled "A Study of Nivolumab Combined With Cabozantinib Compared to Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma". The purpose of this study is to determine whether Nivolumab Combined with Cabozantinib is safe and effective compared to Sunitinib in previously untreated advanced or metastatic renal cell carcinoma

What is the current status of trial NCT03141177?

This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 701 participants. The study started on 2017-07-23. Estimated completion is 2026-01-16.

What conditions does trial NCT03141177 study?

This clinical trial studies the following conditions: Renal Cell Carcinoma.

What interventions are being tested in trial NCT03141177?

The interventions under investigation include: Sunitinib (DRUG), Nivolumab (BIOLOGICAL), Cabozantinib (DRUG), Ipilimumab (BIOLOGICAL).

Who is sponsoring clinical trial NCT03141177?

This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03141177 being conducted?

This trial has 20 study locations across Alabama, Arizona, California, Colorado, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Renal Cell Carcinoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Renal Cell Carcinoma

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.